Abstract
The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Keywords: Escherichia coli, lycopene, promoter engineering.
Current Pharmaceutical Biotechnology
Title:Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering
Volume: 16 Issue: 12
Author(s): Hong-Jie Shen, Jin-Jing Hu, Xi-Ran Li and Jian-Zhong Liu
Affiliation:
Keywords: Escherichia coli, lycopene, promoter engineering.
Abstract: The control of gene expression is critical for metabolic engineering. The multi-copy plasmids has been widely used for high-level expression of genes. However, plasmid-based expression systems are liable to genetic instability and require a selective pressure to assure plasmid stability. In this study, we first constructed a lycopene producer Escherichia coli through promoter engineering. Saccharomyces cerevisiae mevalonate (MEV) pathway was also optimized to balance expression of the top and bottom MEV pathway by using the different strength promoters. The chromosomal heterologous expression of the optimized S. cerevisiae MEV pathway can further improved lycopene production. The final engineered strain, E. coli LYCOP 20, produced lycopene of 529.45 mg/L and 20.25 mg per gram of dry cell weight in the fed-batch culture. The engineered strain does not have a plasmid or antibiotic marker. This strategy used in this study can be applied in pathway engineering of E. coli and other bacteria.
Export Options
About this article
Cite this article as:
Shen Hong-Jie, Hu Jin-Jing, Li Xi-Ran and Liu Jian-Zhong, Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering, Current Pharmaceutical Biotechnology 2015; 16 (12) . https://dx.doi.org/10.2174/1389201016666150731110536
DOI https://dx.doi.org/10.2174/1389201016666150731110536 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Lemongrass (<i>Cymbopogon citratus</i> (D.C.) Stapf) Presents Antitumoral Effect and Improves Chemotherapy Activity in Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism Generalized String Pseudo-Folding Lattices in Bioinformatics: State-of-Art Review, New Model for Enzyme Sub-Classes, and Study of ESTs on Trichinella spiralis
Current Bioinformatics Adhesion Molecules as Targets for the Treatment of Neoplastic Diseases
Current Pharmaceutical Design Heart Failure in the Middle East
Current Cardiology Reviews Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Role of MicroRNAs in Treatment Response in Prostate Cancer
Current Cancer Drug Targets Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Current Pharmaceutical Design Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine